文献速递骨质疏松与代谢性骨病创伤骨科

重大骨质疏松性骨折及髋部骨折后当前与既往使用抗抑郁药或苯二氮䓬类药物与全因死亡率的关系

All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture.
PubMed 文献 · Osteoporos Int · 2019-02-08

在荷兰PHARMO数据库网络中对2002至2011年间65岁及以上首次发生重大骨质疏松性骨折(MOF)的4854例患者进行队列研究,其中1766例为髋部骨折(HF)。骨折后第一年抗抑郁药和苯二氮䓬类药物的累积配药率分别从10.6%升至14.7%和从24.0%升至31.4%。MOF或HF后近期(随访期前31-92天)和既往(>92天前)使用这两类药物与全因死亡风险升高相关,而当前使用(<30天前)与死亡风险无关。

要点

  • MOF后第一年抗抑郁药累积配药率从10.6%升至14.7%,苯二氮䓬类从24.0%升至31.4%。
  • MOF或HF后近期(31-92天前)和既往(>92天前)使用抗抑郁药或苯二氮䓬类与全因死亡风险升高相关。
  • 当前使用(<30天前)与全因死亡风险无关,作者认为可能由健康幸存者偏倚解释。

核心结论

  • MOF后第一年抗抑郁药和苯二氮䓬类药物的配药率显著增加。
  • MOF或HF后近期和既往使用抗抑郁药和苯二氮䓬类药物与全因死亡风险升高相关,当前使用与死亡风险无关。
  • 当前使用与死亡率无关的发现需进一步探索,可能由健康幸存者偏倚解释。

研究设计与样本

  • 在荷兰PHARMO数据库网络内进行的队列研究,纳入2002至2011年间65岁及以上首次记录MOF(髋部、肱骨、前臂和临床椎体骨折)的所有患者。
  • 共4854例患者发生首次MOF,其中1766例发生HF。
  • 使用Cox回归模型分析,校正合并症和合并用药,并按索引骨折类型分层。
  • 平均随访4.6年,分为30天周期。

主要发现

  • MOF后第一年抗抑郁药累积使用率从10.6%升至14.7%,苯二氮䓬类从24.0%升至31.4%。
  • MOF或HF后近期使用(每个随访期前31-92天)抗抑郁药和苯二氮䓬类与全因死亡风险升高相关。
  • MOF或HF后既往使用(>92天前)抗抑郁药和苯二氮䓬类与全因死亡风险升高相关。
  • MOF或HF后当前使用(<30天前)抗抑郁药和苯二氮䓬类与全因死亡风险无关。

局限性

  • 当前使用与死亡率无关的发现需进一步探索,可能由健康幸存者偏倚解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In the first year, after an osteoporotic fracture of a hip, forearm, upper arm, or spine, the dispensing rates of antidepressants and benzodiazepines increased significantly. After those fractures, recent and past use of antidepressants and benzodiazepines was associated with increased all-cause mortality; current use was not associated with mortality risk. INTRODUCTION: It remains unclear to what extent use of antidepressants and benzodiazepines is associated with mortality risk after a major osteoporotic fracture (MOF). We aimed to study the cumulative use of antidepressants and benzodiazepines during the year after MOF or hip fracture (HF) and whether the use was associated with mortality. METHODS: A cohort study was performed within the Dutch PHARMO Database Network including all patients aged 65+ with a first record of MOF (hip, humerus, forearm, and clinical vertebral fracture) between 2002 and 2011. Data were analyzed using Cox regression models, adjusted for comorbidities, and concomitant medication use and broken down to index fracture type. RESULTS: A total of 4854 patients sustained a first MOF, of whom 1766 patients sustained a HF. Mean follow-up was 4.6 years, divided in 30-day periods. The cumulative antidepressant and benzodiazepine use during the first year after MOF increased from 10.6 to 14.7% and from 24.0 to 31.4%, respectively. Recent (31-92 days before each follow-up period) and past use (> 92 days before) of antidepressants and benzodiazepines after MOF or HF was associated with an increased all-cause mortality risk but current use (< 30 days before) was not. CONCLUSION: There is a considerable increase in dispensing rate of antidepressants and benzodiazepines in the first year after a MOF. Recent and past use of these medications was associated with all-cause mortality. The finding that current use was not associated with mortality should be further explored and may probably be explained by the healthy survivor's bias.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. de Bruin IJA, Klop C, Wyers CE, et al. All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture. Osteoporos Int. 2019. PMID: 30737577. doi:10.1007/s00198-019-04851-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。